The use of transvaginal mesh for the treatment of stress urinary incontinence (SUI) and transvaginal repair of pelvic organ prolapse (POP) has been linked to serious complications including vaginal mesh erosion (also called exposure, extrusion or protrusion), pain (including painful sexual intercourse known as dyspareunia), infection, urinary problems, bleeding, and organ perforation.
On March 4, 2011, the FDA notified healthcare professionals and patients of an increased risk of development of cleft lip and/or cleft palate (oral clefts) in infants born to women treated with Topamax (topiramate) during pregnancy.
In an almost unprecedented joint announcement, the FDA and European regulators announced that access to Avandia, a medication to treat diabetes marketed by GlaxoSmithKline, will be severely restricted. Read more »
Today it was reported that GSK has settled more than 700 Avandia cases for a sum reported to be approximately 60 million dollars. These are the first reported settlements involving the drug and represent a small fraction of the total claims believed to be pending. The average settlement would appear to be around 90-95 thousand dollars per case. Read more »
On April 13, 2010 Reuters published a sales forecast predicting the ten top selling drugs for 2014. Contained on that blockbuster list are three drugs, Advair, Remicade and Crestor, which have drawn the scrutiny of consumer safety monitors and attorneys representing injured patients.
Consensus of sales forecasts for world's top 10 drugs in 2014: Read more »